Hematology Pipelines, Trials to Watch, with Steven Fein, MD

EP: 1.Recapping ASH 2024 Highlights, with Steven Fein, MD

EP: 2.Clinically Relevant Updates in Iron Deficiency, with Steven Fein, MD

Now Viewing

EP: 3.Hematology Pipelines, Trials to Watch, with Steven Fein, MD

EP: 4.Updates, News in Sickle Cell Disease, with Steven Fein, MD

EP: 5.Improving Management of Iron Deficiency, with Steven Fein, MD

In part 3 of our 5-part series highlighting ASH 2024 and updates in hematology, Steven Fein, MD, a telehealth hematologist with HemeOnCall, highlights ongoing advancements in clinical trials addressing iron deficiency and hematologic conditions. He discusses a large randomized clinical trial in pregnant women with iron deficiency, comparing oral versus IV iron in a blinded fashion, with a placebo infusion arm ensuring participants remain unaware of their treatment group.

Additionally, Fein points to promising developments in sickle cell disease treatment and breakthrough clinical trials in beta-thalassemia. Both transfusion-dependent and non-transfusion-dependent beta-thalassemia patients have been studied, with the investigational medication mitapivat showing potential. Fein notes that these trials are concluding and will soon undergo FDA review, marking a significant step forward for treatment options in these patient populations.

Relevant disclosures for Fein include Pharmacosmos Therapeutics, Sobi, Amgen, Agios, BeiGene, and others.